---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-039399"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:21:40.240064+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio reports estimated cash and securities of $108M as of Dec 31, 2022

## Summary
- Preliminary estimate of cash, cash equivalents and marketable securities as of Dec 31, 2022: approximately $108.0M.
- Includes $104.6M cash & equivalents and $3.4M marketable securities.
- These are preliminary estimates; final results may differ and will be in Form 10-K.

## SEC filing metadata
- accession: 0001193125-23-039399
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312523039399/0001193125-23-039399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312523039399/d403722d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-039399
- JSON: https://secwatch.observer/filing/0001193125-23-039399.json
- Plain text: https://secwatch.observer/filing/0001193125-23-039399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.